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Regulatory Polymorphisms in the Cyclophilin A
Gene, PPIA, Accelerate Progression to AIDS
Ping An1, Li Hua Wang2, Holli Hutcheson-Dilks3, George Nelson1, Sharyne Donfield4, James J. Goedert5,
Charles R. Rinaldo6, Susan Buchbinder7, Gregory D. Kirk8, Stephen J. O’Brien3, Cheryl A. Winkler1*
1 Laboratory of Genomic Diversity, Science Applications International Corporation-Frederick, National Cancer Institute-Frederick, Frederick, Maryland, United States of
America, 2 Basic Research Program, Science Applications International Corporation-Frederick, National Cancer Institute-Frederick, Frederick, Maryland, United States of
America, 3 Laboratory of Genomic Diversity, National Cancer Institute, Frederick, Maryland, United States of America, 4 Rho Incorporated, Chapel Hill, North Carolina, United
States of America, 5 Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America,
6 Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, United States of America, 7 San
Francisco Department of Public Health, San Francisco, California, United States of America, 8 Department of Epidemiology, Johns Hopkins University Bloomberg School of
Public Health, Baltimore, Maryland, United States of America

Human cyclophilin A, or CypA, encoded by the gene peptidyl prolyl isomerase A (PPIA), is incorporated into the HIV
type 1 (HIV-1) virion and promotes HIV-1 infectivity by facilitating virus uncoating. We examined the effect of single
nucleotide polymorphisms (SNPs) and haplotypes within the PPIA gene on HIV-1 infection and disease progression in
five HIV-1 longitudinal history cohorts. Kaplan-Meier survival statistics and Cox proportional hazards model were used
to assess time to AIDS outcomes. Among eight SNPs tested, two promoter SNPs (SNP3 and SNP4) in perfect linkage
disequilibrium were associated with more rapid CD4þ T-cell loss (relative hazard ¼ 3.7, p ¼ 0.003) in African Americans.
Among European Americans, these alleles were also associated with a significant trend to more rapid progression to
AIDS in a multi-point categorical analysis (p ¼ 0.005). Both SNPs showed differential nuclear protein-binding
efficiencies in a gel shift assay. In addition, one SNP (SNP5) located in the 59 UTR previously shown to be associated
with higher ex vivo HIV-1 replication was found to be more frequent in HIV-1-positive individuals than in those highly
exposed uninfected individuals. These results implicate regulatory PPIA polymorphisms as a component of genetic
susceptibility to HIV-1 infection or disease progression, affirming the important role of PPIA in HIV-1 pathogenesis.
Citation: An P, Wang LH, Hutcheson-Dilks H, Nelson G, Donfield S, et al. (2007) Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS.
PLoS Pathog 3(6): e88. doi:10.1371/journal.ppat.0030088

which confers HIV-1 resistance in owl monkey [9–11]. Both
TRIM5a and CypA recognize and act on the capsid of HIV-1,
but apparently confer opposite effects. TRIM5a restricts
HIV-1 by promoting premature disassembly of HIV-1 capsid
[12], while CypA increases viral infectivity by facilitating
proper uncoating. Although the interaction between CypA
and TRIM5a is still unclear, it appears that the modulation of
HIV-1 infectivity by CypA is independent of TRIM5a [11,13–
15]. It has been postulated that binding of CypA to capsid
protects HIV-1 from an unknown restriction factor in
humans [15].
The study of the inﬂuence of human gene variation on
susceptibility to HIV-1 infection and progression is an
approach that may reveal the in vivo host factor HIV-1
interactions and their epidemiologic importance at the
population level. With this approach we have identiﬁed
several AIDS-modifying variants in genes TRIM5 [16],

Introduction
As an obligate intracellular parasite, HIV type 1 (HIV-1)
utilizes host cell factors for its replication. Human cyclophilin
A (CypA), also known as peptidyl prolyl isomerase A (PPIA), is
a ubiquitous cytoplasmic protein (by convention, we refer to
the protein as CypA and the gene as PPIA). CypA has long
been known for its incorporation into HIV-1 virions and its
important role in facilitating HIV-1 replication in host cells
[1,2]. CypA is a member of the cyclophilin family, members of
which all possess peptidyl-prolyl cis/trans isomerase activity.
Peptidyl prolyl cis/trans isomerases (PPIAses) catalyze the cis/
trans isomerization of prolyl peptide bonds and are believed
to be involved in protein folding [3]. The incorporation of
CypA into the HIV-1 virion capsid is mediated through the
direct binding between prolyl peptide bond located in a
proline-rich loop of the fourth and ﬁfth helices of the HIV-1
capsid and the active sites of CypA [4,5]. Disruption of CypA
incorporation, either by HIV-1 Gag mutations or by cyclosporine A, an immunosuppressive drug that prevents HIV-1
Gag binding to CypA, leads to an attenuation of HIV-1
infectivity [2,6]. Braaten and Luban found that HIV-1
replication was decreased in CypA-null human CD4þ T cells,
in which the gene encoding CypA (PPIA) was deleted through
homologous recombination [7]. CypA is therefore an important host factor that regulates HIV-1 replication.
Recently, the role of CypA in HIV-1 has gained even
greater attention with the discovery of a fusion protein of
CypA and TRIM5a, a host restriction factor against HIV-1 [8],
PLoS Pathogens | www.plospathogens.org
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Author Summary
Individual risk of acquiring HIV type 1 (HIV-1) infection and
developing AIDS is not equal; some people are more prone to
HIV/AIDS than others. Susceptibility to HIV-1/AIDS is likely determined by a combination of environmental, viral, and host genetic
factors. Genetic variations in host cellular factors involved in HIV-1
cell entry, replication, and host defense have been found to affect
susceptibility to HIV-1/AIDS. In this report, we focused on the gene
PPIA that encodes cyclophilin A, a human cellular protein that is
incorporated into the HIV-1 virion and promotes viral replication. We
studied genetic variation in the PPIA gene in persons with different
susceptibility levels to HIV-1 infection or different rates of disease
progression. We found that individuals who processed two functional variants in the promoter region of PPIA had higher risk of
CD4þ T-cell loss or progression to AIDS-defining diseases. We also
observed that an additional variant occurred more frequently in HIV1-infected individuals compared to HIV-1-exposed, but uninfected,
individuals. These results suggest that genetic variation in PPIA may
influence host susceptibility to HIV-1 infection or disease progression and targeting PPIA might provide therapeutic benefit.

Figure 1. Gene Map, SNPs, and Haplotypes in the Human PPIA on
Chromosome 7p13
Coding exons are marked by green blocks, and 59 and 39 UTRs by light
green blocks. Hatched black boxes represent Alu repeats. Haplotype
structure and frequencies are shown in the middle panel. The
corresponding nucleotides in the chimpanzee and allele frequencies of
the SNPs are presented in the bottom panel. MAF, minor allele frequency
of SNPs (based on EA frequency).
doi:10.1371/journal.ppat.0030088.g001

APOBEC3G [17], and CUL5 [18] that encode human innate
HIV-1 restriction factors or related proteins. In a recent
study performed in the Swiss HIV Cohort Study, a variant of
PPIA was implicated as a potential factor affecting HIV-1
disease progression [19]. As CypA is an essential human
protein for completion of the HIV-1 life cycle, we have
assessed the inﬂuence of genetic variation in the PPIA gene
on HIV-1 infection and disease progression in ﬁve United
States–based HIV-1 natural history cohorts.

one in intron 4, and one in the second Alu repeat region
upstream of the putative promoter. No SNPs were found in
the coding regions. These SNPs and four additional SNPs
available from dbSNP database located in regions not
detected by our sequencing were selected for genotyping in
the AIDS cohorts (Figure 1 and Table 1). SNP1 genotypes
deviated from the frequencies expected under the HardyWeinberg equilibrium (p , 0.001), probably due to its
location in the Alu repetitive element; thus, SNP1 was
excluded in the analysis. SNP2 was also excluded from
analysis due to its rarity. The genotypic frequencies of all
other SNPs conform to Hardy-Weinberg expectations.
Allele frequency distributions of PPIA SNPs differed in EA
and AA with Fst values ranging from 0.03 to 0.40 (average
0.22). The difference is particularly pronounced for SNPs 7, 8,

Results
Description of PPIA Variations
The PPIA gene is approximately 7 kb in length, consisting
of ﬁve exons (Figure 1A). Using PPIA-speciﬁc primers we
resequenced virtually the entire PPIA gene to screen for
single nucleotide polymorphisms (SNPs) in 92 European
Americans (EA) and 92 African Americans (AA). Seven
polymorphisms were discovered: three in the putative
promoter region, one in the 59 UTR, one in the 39 UTR,

Table 1. Characterization of PPIA SNPs
SNP

dbSNP rs
Number

Nucleotide Position
and Changesa

Location

1
2
3
4
5
6
7
8
9
10
11

rs4720485

489 A/T
1167 C/T
1575 C/G
1604 C/G
1650 A/G
2629 A/G
2653 A/C
4943 C/T
6193 A/G
6576–6577 /AG
1981 G/Ab

Alu repeat
Promoter
Promoter, 10 to TATA
Promoter, 11 to mRNA initiation site
59 UTR, 9 to CDS
Intron 1
Intron 1
Intron 4
Intron 4
39 UTR
39 UTR

rs8177826
rs6850
rs6970925
rs3735481
rs6463247
rs10249442
rs8177830
rs6904

a

Nucleotide position is numbered according to GenBank sequence X52851.
Nucleotide position is numbered according to GenBank sequence NM_021130.
doi:10.1371/journal.ppat.0030088.t001
b
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Haplotype structure and maximum likelihood haplotype
frequencies were estimated with the EM algorithm. There
were, in total, eight haplotypes with minor allele frequency
.1% in either population (Figure 1B). Five or six haplotypes
were present in EA or AA, respectively, accounting for .97%
of total sampled chromosomes. Among these, only three
common haplotypes (minor allele frequency .5%) were
shared between AA and EA (hap1, 2, and 4). Diverse
distributions of haplotype frequencies between AA and EA
were seen as for SNPs.

Figure 2. LD Structure of PPIA SNPs in AA and EA
LD Structure of PPIA SNPs in AA (A) and EA (B). Pairwise D9 plots and
haplotype blocks obtained from HAPLOVIEW. Pairwise D9 values (%)
were indicated in triangle squares except for those of D9 of 1.0. High D9
values were shown in bright red (LOD .¼ 2) or light blue squares (LOD
, 2), and low D9 values were shown in light red (LOD .¼ 2) and white
squares (LOD , 2). Single haplotype block was defined by the solid
spine algorithm.
doi:10.1371/journal.ppat.0030088.g002

Effect of PPIA SNPs and Haplotypes on Susceptibility to
HIV-1 Infection
We compared the PPIA SNP allele and haplotype frequency
distributions among three groups with increasing resistance
to HIV-1 infection: seroconverters (SCs), seronegatives (SNs)
belonging to an HIV-1 risk group, and those with documented high-risk exposures to HIV-1 who remain uninfected
(HREU) (Table 2). The minor allele of SNP5 (G) was carried in
13.7% of SCs, 13.5% of SNs, and 9.5% of HREU, respectively
(Mantel-Haenszel trend test, p ¼ 0.21). The reduced carriage
of SNP5G in HREU was signiﬁcant when SCs were compared
to HREU (odds ratio ¼ 1.78, p ¼ 0.02), suggesting that the
SNP5G allele carriers may have increased susceptibility to
HIV-1 infection (Table 2). No distortion of frequency
distribution between risk groups were observed for all other
SNPs in AA or EA (unpublished data).

9, 10, and 11 (Fst, 0.30–0.40), where the minor alleles are
reversed in the two populations (Figure 1).

Linkage Disequilibrium and Haplotypes of PPIA SNPs
The extent of linkage disequilibrium (LD) among eight
SNPs was assessed by calculating all pairwise D9 values,
separately for AA and EA (Figure 2A and 2B). Strong LD was
observed among almost all SNPs in AA (D9 range 0.87–1.0)
and even stronger LD in EA (D9 range 0.97–1.0). SNP3 and
SNP4 were in perfect LD in both populations (D9 ¼ 1, r2 ¼ 1).
As each of these two SNPs carries the same information
content, SNP4 was selected as a proxy for SNP3 in the
analysis. The eight SNPs in both population groups formed a
single LD block as deﬁned by the solid spine of LD method
[20]. This provided a justiﬁcation to use all eight SNPs
spanning the entire region as one block for subsequent
haplotype-based association analyses.
Among AA, SNP6 presented intermediate level of LD (D9
;0.60) with the SNPs downstream (SNP8–11); SNP6–SNP8
recombinant G-C haplotype had a frequency of 5%. Among
EA, SNP5 had weak LD with SNP6–11 (D9 0.47–0.71); the
recombinant haplotype SNP5–SNP6 (G-G) had a frequency of
2.5%. This suggests an occurrence of recombination in the
region between SNP5 and SNP8. The presence of multiple
Alu elements in PPIA may have introduced the recombination event by promoting genomic instability [21].

PPIA SNPs and AIDS Progression
We analyzed AA and EA separately since the SNP
frequencies differed between the two groups. The Cox
proportional hazards model was employed to test the
potential differential impact of SNPs on the rates of
progression to CD4 ,200 or to AIDS clinical diseases (Table
3). To minimize the number of SNPs to be tested, we only
tested the unique SNPs represented in each population, i.e.,
only one SNP was tested for those in perfect LD (r2 ¼ 1). Six
and four SNPs were analyzed in AA and EA, respectively. Two
SNPs in AA (SNPs 4 and 5) and three SNPs in EA (SNPs 4, 5,
and 7) showed signiﬁcant or near-signiﬁcant effects (Table 3).

Effect of SNP4 on AIDS Progression
Among AA SCs, the minor allele of SNP4 (the G allele) was
associated with accelerated loss of CD4þ T cells (relative

Table 2. Effects of PPIA SNP4 and SNP5 on HIV-1 Infection Risk in EA
SNP

Risk Group

n

SNP4
SC
SN
HREU

659
447
155

SC
SN
HREU

652
603
153

SNP5

Genotype

SC versus SN or HREU

Number of Carriers (Frequency)

OR (95% CI)a

CC
574
392
130
AA
485
458
128

(0.871)
(0.877)
(0.839)
(0.744)
(0.76)
(0.837)

CG
83 (0.126)
53 (0.119)
23 (0.155)
AG
155 (0.238)
130 (0.216)
21 (0.137)

GG
2 (0.003)
2 (0.005)
1 (0.007)
GG
12 (0.002)
15 (0.003)
4 (0.003)

p

CG þ GG versus CC
1.05 (0.73–1.52)
0.77 (0.47–1.25)

0.77
0.29

AG þ GG versus AA
1.09 (0.84–1.41)
1.76 (1.11–2.80)

0.52
0.02

a

OR represents the odd ratio of being an HIV-1-SC compared to being either HIV-1-SN or HREU.
n, number of individuals.
doi:10.1371/journal.ppat.0030088.t002
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Table 3. Effects of PPIA SNPs on AIDS Progression in AA and EA
SNP Number

SNP4(SNP3)a
SNP5
SNP6
SNP7b
SNP8
SNP11c

Endpoint

CD4,200
AIDS-87
CD4,200
AIDS-87
CD4,200
AIDS-87
CD4,200
AIDS-87
CD4,200
AIDS-87
CD4,200
AIDS-87

AA (n ¼ 284–290)

EA (n ¼ 643–650)

RH

95% CI

p

RH

95% CI

p

3.7
2.03
0.67
0.86
1.16
1.20
1.04
0.82
0.72
0.64
0.88
0.84

1.59–8.63
0.63–6.53
0.44–1.01
0.50–1.48
0.78–1.74
0.71–2.04
0.60–1.82
0.40–1.67
0.39–1.34
0.29–1.43
0.49–1.60
0.38–1.87

0.003
0.24
0.06
0.58
0.46
0.49
0.88
0.58
0.30
0.28
0.68
0.68

1.19
1.34
0.95
1.26
1.16
1.05
1.08
1.32

0.88–1.62
0.97–1.85
0.74–1.22
0.98–1.64
0.92–1.45
0.82–1.34
0.85–1.37
1.03–1.70

0.26
0.07
0.70
0.08
0.21
0.71
0.55
0.03

The Cox proportional hazards model was employed to test the impact of SNPs on the rates of progression to CD4,200 or to AIDS clinical diseases (AIDS-87); p-values were from a Wald
test.
a
SNP3 and SNP4 are in perfect LD.
b
SNP7 is representative of SNP8, SNP9, and SNP11 in EA.
c
SNP9 is representative of SNP11 in AA.
n, number of individuals.
doi:10.1371/journal.ppat.0030088.t003

hazard [RH] ¼ 3.7, 95% conﬁdence interval [CI] ¼ 1.59–8.63)
in a Cox proportional hazards model (Table 3). After
stratifying by cohort in the Cox regression analysis, this
association became slightly stronger (RH ¼ 4.08, 95% CI ¼
1.71–9.70). Kaplan-Meier survival analysis presented a clear
separation of curves stratiﬁed for the SNP4 C/C and C/G
genotypes (G/G absent) on progression to CD4 ,200 in AA (p
¼ 0.002, log-rank test, Figure 3). Notably, all SNP4 carriers
progressed to CD4 ,200 within 6 y. The effect on AIDS-1987
was in the same direction but short of signiﬁcance (Table 3).
Identical results were seen for SNP3 (unpublished data).
Among EA SCs, a trend of accelerated progression to AIDS1987 was also observed, though short of signiﬁcance (RH ¼
1.34, p ¼ 0.07, Table 3).
To afﬁrm the observed genetic inﬂuence of SNP4, we
performed a categorical analysis of HIV-1-infected people

that included seroprevalents (SPs) in the long-term survivors
(Figure 4). SPs who had remained AIDS-free for greater than
7.5 y for AA or 10 y for EA after study enrollment (the median
time to AIDS for each) were included in this analysis. The
frequency distributions of SNP4 in six discrete time intervals
progressing to disease outcome after HIV-1 infection were
tested for statistical trend using a Mantel-Haenszel test. As
shown in Figure 4, the SNP4 G allele occurred more
frequently among fast progressors in both AA and EA. With
an increased sample size of 389 patients in AA, a signiﬁcant
trend toward rapid CD4 loss is still preserved (p ¼ 0.04, Figure
4A). Among 970 EA patients, the trend toward rapid
progression to AIDS was more pronounced (p ¼ 0.004)
(Figure 4B). Thus, the results from SC plus SP groups
corroborate the ﬁndings from the SC-alone survival analyses,
indicating that the accelerating effect of SNP4 is consistent in
both AA and EA populations.

PPIA SNP5 and AIDS Progression
In a Swiss Caucasian HIV-1 cohort, SNP5G, referred to as
1650A/G [19], was reported to be associated with a rapid CD4
cell depletion and with a trend toward higher in vitro HIV-1
replication [19]. In our analysis of EA SCs, SNP5G showed a
nonsigniﬁcant trend toward rapid progression to AIDS-1987
(RH ¼ 1.26, p ¼ 0.08), but had no effect on CD4 cell depletion,
while an opposite trend was observed in AA (Table 3). In a
categorical analysis of combined samples from SCs and SPs,
SNP5G also had no impact on both outcomes in both EA and
AA (p . 0.23, unpublished data). Therefore, this study offers
no convincing evidence for SNP5 association with disease
progression in either EA or AA.

Effects of PPIA Haplotypes on AIDS Progression
In the haplotype analysis, we ﬁrst used the Cox regression
model to test the global null hypothesis of no association
between haplotype frequency and AIDS progression, by
comparing a model with all haplotypes to the covariants-

Figure 3. Kaplan-Meier Survival Curve Analysis of SNP4 on Progression to
CD4þ Cells ,200/mm3 in AA
doi:10.1371/journal.ppat.0030088.g003
PLoS Pathogens | www.plospathogens.org
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Table 4. Effects of PPIA Haplotypes on AIDS Progression
Haplotype CD4 ,200, AA (n ¼ 266)

Hap2
Hap1
Hap3
Hap4
Hap5
Hap6
Hap7
Hap9

RH

95% CI

p

1.00
1.09
1.42
1.62
0.97
1.37
5.39

Referent
0.72–1.64
0.85–2.38
0.98–2.68
0.45–2.07
0.52–3.61
1.93–15.0

0.70
0.18
0.06
0.93
0.53
0.01

AIDS-87, EA (n ¼ 603)
RH

95% CI

p

1
1.48

Referent
0.84–2.60

0.18

1.24

0.86–1.78

0.25

2.17
2.55

1.07–4.41
0.99–6.60

0.032
0.053

The Cox proportional hazards model was used to test the impact of haplotypes on the
rates of progression to CD4 ,200 or to AIDS-87. p-values were from a Wald test. Hap2,
common in both AA and EA, was used as referent.
n, number of individuals.
doi:10.1371/journal.ppat.0030088.t004

This suggests that CypA and TRIM5a likely act independently, consistent with recent in vitro observations [11,13–
15,23].

Electrophoretic Mobility-Shift Assay
As SNP3, 4, and 5 reside in the regulatory region of PPIA,
we performed gel shift assays to assess whether these SNPs
differentially bind to transcriptional factors (Figure 5). In this
experiment, ;25-bp DNA probes containing either of the
SNP alleles were incubated with the nuclear extracts from
Th1 cytokine-stimulated human T lymphocytes. Both SNPs
showed differential binding afﬁnity to nuclear protein(s) with
the same mobility (Figure 5A, top band). Averaged from two
independent experiments, a 4-fold decrease or 2.8-fold
increase in the band density was observed for the minor
allele of SNP3 (G) and SNP4 (G), respectively. The cold
unlabeled oligonucleotides with minor alleles were unable to
compete with wild-type oligonucleotides, suggesting the
bindings are speciﬁc. These results indicate that these two
SNPs within the promoter alter the binding afﬁnity with
certain transcriptional protein(s). On the contrary, no
obvious differential binding was observed for SNP5 (Figure
5A).
In silico analysis of the sequence at these three SNP sites by
using TESS software also predicted differential binding for
SNP3 and 4, but not for SNP5. SNP3 and 4 were each located
in one of the consensus-binding motifs of transcription factor
SP1, as shown in Figure 5B. The local sequence with SNP3C is
identical to the consensus sequence of SP1 site, GGGGCC,
whereas SNP3C.G change perturbs this motif. In contrast,
the sequence with SNP4C has two mismatch sites compared
to an alternative consensus sequence of SP1 site,
GAGGCGGGGC, whereas SNP4C.G reduced the mismatch
to one, predicting a stronger binding. There is, therefore, a
plausible biochemical basis for the differential binding
afﬁnity observed in the gel shift experiment. These results
also suggest that SNP3 and SNP4 affect transcription, likely
through their interactions with SP1. The sequence of the
region of human PPIA promoter resided in by SNP3 and
SNP4 was compared to the corresponding sequence from
other species (Figure 5C). SNP3 and SNP4 are both located in
the highly conserved regions. The C allele of SNP3 is present

Figure 4. Disease Categorical Analysis Using both SCs and SPs for the
Effect of SNP4 on Progression to CD4 ,200 in AA and to AIDS-87 in EA
Only SPs with greater than 7.5 y (for AA [A]) or 10 y (for EA [B]) of survival
time, the median survival time of the SCs, were included in the analysis.
The frequencies of the SNP4 C/G genotype in five intervals after
seroconversion are plotted and tested for statistical trends using MantelHaenszel v2 test. Numbers of patients are listed above the bar.
doi:10.1371/journal.ppat.0030088.g004

only model. This revealed that the global distributions of
haplotype frequencies were signiﬁcantly or near-signiﬁcantly
different for the outcome of CD4 ,200 in AA (p ¼ 0.01) and
AIDS-87 in EA (p ¼ 0.08). The distortion of frequency
distribution was mainly attributable to one haplotype
(Hap7) (Table 4). Hap7, the only haplotype carrying SNP4G
(Figure 1), was associated with accelerated progression to
AIDS in both AA and EA (Table 4), consistent with the results
from SNP analysis.

Interactions between TRIM5 and PPIA Variants
Because TRIM5a interferes with and CypA facilitates postentry uncoating of the HIV-1 capsid, it is possible that there
may be genetic interactions between two genes. Potential
interactions were tested only between variants in two genes
with functional plausibility or high strength of association.
Speciﬁcally, PPIA SNP4 was tested for its interaction with
TRIM5-rs16934386 and TRIM5-R136Q, which was previously
reported using the same patient population to be associated
with HIV-1 infection but not progression [22]. In the Cox
regression model analysis, we observed no obvious interaction for infection or progression (p . 0.15, unpublished data).
PLoS Pathogens | www.plospathogens.org
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Figure 5. Binding Affinity of Nuclear Factors to the SNP-Containing Fragments in the 59 Regulatory Regions of PPIA and the Sequence Context of the
Region
(A) Gel shift analysis of SNP3, SNP4, and SNP5 in the 59 regulatory region of PPIA. Nuclear extracts from human T lymphocytes induced by IL4 were
bound to the DNA fragment containing the C or G allele of SNP3, the C or G allele of SNP4, and the A or G allele of SNP5, respectively. The arrowhead
indicates the band showing differential binding of nuclear factor(s) to the oligonucleotides. The bands below the arrow may represent nonspecific
complexes and the bands at the bottom are free probes.
(B) Sequence context of SNP3 and SNP4 and comparison to the consensus-binding motifs of transcription factor SP1. SNPs 3 and 4 (located at positions
1575 and 1604 in the sequence X52851, and 85 and 59, to the ATG start codon, respectively) are in perfect LD. SNP3C.G change predicts a loss of
binding to a SP1 factor, while SNP4C.G change predicts a stronger binding to a SP1 factor.
(C) The interspecies alignments of a segment of the PPIA promoter containing SNP3 and SNP4. Conserved regions are underlined and SNP sites are
colored.
doi:10.1371/journal.ppat.0030088.g005

in both primates and rodents. The C allele of SNP4 occurs
only in primates and the minor allele G occurs in rodents,
suggesting a possible association with speciation. These
interspecies data support the hypothesis that SNP3 and
SNP4 changes may have functional consequences.

sequence identity to rhesus monkey and mouse, respectively.
The nucleotide sequence of PPIA is 98% identical between
human and chimpanzee. No variation in the coding sequence
of human PPIA was found in this study or in the dbSNP
database. This suggests that differential genetic impact of
PPIA SNPs and haplotypes on infection and progression are
likely due to regulatory region variation affecting protein
levels. The regulation and promoter function of human PPIA
is still undeﬁned. PPIA is highly expressed in almost all cell
types and is considered a housekeeping gene. Sequence
analysis revealed that PPIA promoter contains a TATA box
and two SP1 binding sites and is highly GC-rich (;70%) with
overrepresented CpG dinucleotides [24]. In this study, we
identiﬁed two SNPs, each located in two additional SP1
binding elements. SP1 is generally believed to function as a
transactivating factor for many housekeeping genes [25].
These two SNP changes, SNP3G and SNP4G, always occurring
together through LD, had opposite effects on the nuclear
protein binding. Assuming the predicted stronger SP1 binding effect of SNP4 is dominant over the weaker SP1 binding
of SNP3, a higher PPIA gene expression would be predicted.
This would be consistent with more rapid disease course as
observed in this study.
Based on our analyses of eight SNPs covering the entire
gene region of PPIA and their haplotypes, we found that the
PPIA disease-modifying effects were most likely afforded by
promoter SNP3 or SNP4 and the associations with the
downstream SNPs 7–11 were largely due to tracking of these

Discussion
The role of CypA in promoting HIV-1 replication has been
well established through extensive in vitro experiments
[1,2,6,7]. In this study, we have undertaken a systematic
investigation of the association between genetic variations in
the PPIA gene and susceptibility to HIV-1 infection and
disease progression in HIV-1 natural history cohorts. We
found that two promoter variants in perfect LD, SNP3 and
SNP4, in PPIA, were associated with rapid HIV-1 disease
progression. This effect was revealed for CD4 cell depletion
or for AIDS progression, reﬂecting early or late stage of
disease progression, in AA and EA, respectively. The racial
difference in the strength or timing of the effects may be due
to interactions with other sequence variations that are
distributed differently in two populations or to immunologic
and viral variables. We further found that both SNPs had
differential binding efﬁciency to nuclear proteins in the gel
shift experiment. These ﬁndings suggest that the functional
promoter SNP3/SNP4 inﬂuences HIV-1 disease progression.
PPIA in human encodes a 165-amino acid protein that is
highly conserved across species, with 100% and 96%
PLoS Pathogens | www.plospathogens.org
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tional approaches, we have identiﬁed two promoter SNPs in
PPIA as potential genetic modiﬁers of HIV-1 disease
progression. Our ﬁndings corroborate the notion that genetic
variation of PPIA inﬂuences AIDS pathogenesis and provide
in vivo evidence that CypA is a critical host protein in
interaction with HIV-1. Manipulation of PPIA may be
considered as a plausible option for anti-HIV-1 therapeutic
development as previously explored [29].

two SNPs through LD. In a previous report, Bleiber et al.
studied the ex vivo HIV-1 infectivity in CD4þ T cells from
healthy individuals carrying the SNP4 and SNP5 alleles
(named as PPIA-1604 and PPIA-1650, respectively, in the
Bleiber’s report), as well as their impact on the CD4 gradient
(from CD4þ T-cell counts 500/mm3 to 200/mm3) among SPs
enrolled in the Swiss HIV cohort, largely comprised of
Caucasians [19]. In the ex vivo experiment, both SNPs showed
nonsigniﬁcant tendencies toward greater HIV-1 replication,
with the effects of SNP5 being more pronounced. In the
population study, both SNPs were associated with faster CD4þ
T-cell depletion in a model also containing two other
candidate genes (model 2); with the SNP5 of PPIA effect
again being more pronounced. Thus, the detrimental effect
of SNP4 observed from these two studies is largely consistent.
In contrast, no evidence supporting a role of SNP5 in AIDS
progression was found, although the SNP5 G allele was
carried signiﬁcantly less often in HREU than in SC but was
similarly distributed in SC and SN. Thus, the role of CypA
polymorphism in HIV-1 infection remains inconclusive and
warrants further investigation. Taken together, the association and functional results from these two studies point to a
role of PPIA genetic variation in HIV-1/AIDS. In future
studies, it may be informative to determine the mechanism of
association between PPIA variants and host susceptibility to
HIV-1 infection or disease progression in view of the
interaction between CypA and the capsid domain of the
Gag polyprotein.
Population-based genetic association studies provide a
powerful approach to uncovering host genes that confer
disease susceptibility or resistance. This approach has led to
identiﬁcation of various genetic factors that affect HIV-1/
AIDS, and has provided unique insights into the host HIV-1
interaction [26,27]. The successful identiﬁcation of true
genetic associations requires a large sample size (to minimize
the type II error), replication in independent studies (to ward
off type I error), and plausible functional evidence (to infer
causal relationship). In this study, the plausible geneticmodifying role of PPIA is supported by replication in two
independent ethnic groups and the demonstration that SNPs
3 and 4 are each associated with altered binding afﬁnities to
transcription factors. Moreover, the previous independent
study also provides supportive association and functional
evidence [19].
Our comprehensive analysis of nearly all variant alleles and
their haplotypes in the PPIA gene is, in essence, equivalent to
a gene-based approach [28]. A major problem facing genetic
association studies is the difﬁculty in replication, particularly
for single SNP associations. One reason for failure to
replicate previous studies is due to potential differences in
allele frequencies and LD structure across populations. Genebased replication has recently been advocated as a gold
standard for replication studies [28]. The entire gene with
prior SNP association is considered the functional unit and is
examined for association with effectively all genetic variation
in the gene. Nonreplication due to population differences
may be minimized as local allele frequencies and LD structure
from study populations are considered with this approach
[28]. Thus, our comprehensive survey of PPIA genetic
variation and LD structure may facilitate future comparisons
of replication studies using a gene-based approach.
In summary, through genetic epidemiological and funcPLoS Pathogens | www.plospathogens.org

Materials and Methods
Study participants. Study participants were enrolled in ﬁve United
States–based natural history HIV/AIDS cohorts. AIDS Link to the
Intravenous Experience (ALIVE) is a community-based cohort of
intravenous injection drug users in Baltimore enrolled in 1988–1989
[30], consisting of 92% AA; Multicenter AIDS Cohort Study (MACS) is
a longitudinal prospective cohort of men who have sex with men
(MSM) from four United States cities: Chicago, Baltimore, Pittsburgh,
and Los Angeles, enrolled in 1984–1985 [31], consisting of 83% EA
and 10% AA; the San Francisco City Clinic Study (SFCC) is a cohort
of MSM originally enrolled in a hepatitis B study in 1978–1980 [32],
consisting of 96% EA; Hemophilia Growth and Development Study
(HGDS) is a multicenter prospective study that enrolled children with
hemophilia who were exposed to HIV-1 through blood products
between 1982 and 1983 [33], consisting of 72% EA and 11% AA; the
Multicenter Hemophilia Cohort Study (MHCS) is a prospective study
that enrolled persons with hemophilia [34], consisting of 90% EA and
6% AA. The participant group is comprised of HIV-1 SCs (infected
after study enrollment), SPs (infected at study enrollment), SNs, and
HREU. The MACS, MHCS, SFCC, and ALIVE cohorts consist of both
SCs and SPs among HIV-1-infected individuals. Due to the potential
frailty bias (missing the most rapid progressors to AIDS and death)
among SPs, only SCs from these four cohorts were used in the survival
analysis. SPs were also included for allele frequency estimation,
haplotype inference, and disease categorical analysis. The number of
participants studied in each risk or disease category was as follows: SC
¼ 654 EA, 295 AA; SN ¼ 604 EA, 350 AA; HREU ¼ 153 EA, 81 AA; and
SP ¼ 1199 EA, 773 AA. Of 290 AA SCs, 237, 42, 5, and 5 were from
ALIVE, MACS, MHCS, and HGDS, respectively.
The date of seroconversion after study enrollment was estimated as
the midpoint between the last seronegative and ﬁrst seropositive
HIV-1 antibody test; only individuals with less than 2 y elapsed time
between the two tests were included in the seroconverter progression
analysis. The censoring date was the earliest of the date of the last
recorded visit, or December 31, 1995 for the MACS, MHCS, HGDS,
and SFCC or July 31, 1997 for the ALIVE cohort to avoid potential
confounding by highly effective anti-retroviral therapy (HAART).
The censoring date was extended in the ALIVE cohort because of
delayed uptake of HAART in this group [30,35].
HIV-1-uninfected individuals were classiﬁed into two categories
based on individual’s documented exposure levels to HIV-1. HREU
individuals were those 80 AA and 145 EA with documented high-risk
exposure through sharing of injection equipment [36], who had anal
receptive sex with multiple partners [37], or transfusions with Factor
VIII clotting factor prior to 1984, when heat treatment was initiated
[38]. SN individuals (n ¼ 420 and 571, respectively, for AA and EA) are
those enrolled in the cohorts who remained HIV-seronegative despite
ongoing or prior risk activity.
The study protocols were approved by the Institutional Review
Boards of participating institutions and informed consent was
obtained from all study participants.
Identiﬁcation of SNPs. Nucleotide polymorphisms were discovered
in a panel of 92 EA and 92 AA, representing the extremes of the
distribution for rapid and slow progression to AIDS and HREU. A
nonisotopic RNA cleavage assay following PCR was employed to
screen for polymorphisms [39]. PPIA has a high degree of homology
to multiple processed pseudogenes that varies from 75% to 95% in
the exon regions. PPIA also contains six copies of Alu repeats, each
with a length of approximately 300 bp, located in the immediate
upstream of the putative promoter region and introns [24]. Sequence
comparison and BLAST search were performed to select PPIAspeciﬁc PCR primers. Overlapping primers covered nearly the entire
PPIA gene region including the putative promoter region, 59 and 39
UTRs, all ﬁve exons, as well as the Alu repeat regions. A part of intron
1 was not covered due to the high GC content. Primer sequences are
presented in Table S1 and are numbered according to the GenBank
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DNA sequence X52851. Additional intronic SNPs were selected from
NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP) and HapMap databases (http://www.hapmap.org), by considering location, spacing, and
allele frequency at least 10%. Haplotype tagging (ht)SNPs were given
preference in the SNP selection. The ancestral allele state of the SNPs
was based on a reference chimpanzee sequence.
Genotyping of SNPs. Genotyping was performed using PCRrestriction fragment length polymorphism (PCR-RFLP) assay or
TaqMan assays. PCR-RFLP was carried out with 35 cycles of
denaturing at 94 8C for 30 s, annealing at 60 8C for 30 s, and
extension at 72 8C for 45 s. The PCR product was digested with
respective restriction enzymes (New England Biolabs, http://www.neb.
com) overnight and then separated on 3% agarose gels. TaqMan
assays were obtained from the Assay-by-Demand service of Applied
Biosystems (http://www.appliedbiosystems.com). Genotyping primers
and conditions were presented in Table S2. Eight water controls were
included on each plate to monitor the potential PCR contamination,
and 10% of SC and HREU samples were genotyped twice. The
genotypes obtained were free of water contamination or of
inconsistencies between duplicates.
Statistical analysis. To assess the difference in allele frequency
distribution in two populations, we performed a contingency v2 test
for each marker to test the null hypothesis that the allele frequencies
are the same in the two populations. Fst values were estimated by
Wier and Cockerham’s method [40].
Pairwise LD was quantiﬁed using the absolute value of D9. Absolute
values of D9 range from 0 for independence to 1 for complete LD
between the pairs of loci. LD plots were generated utilizing
Haploview (http://www.broad.mit.edu/mpg/haploview) [20]. A triangular matrix of D9 value was used to demonstrate LD patterns within AA
and EA. Haplotype blocks were estimated using the solid spine of LD
method [20]. Haplotype blocks were deﬁned with a default algorithm
based on conﬁdence intervals of D9 [41], or the solid spine of LD
method, which creates blocks of SNPs that have contiguous pairwise
D9 values of greater than 0.8. With the latter method, the ﬁrst and last
SNPs in a block are in strong LD with all intermediate SNPs, but the
intermediate SNPs are not necessarily in LD with each other [20].
Eight SNP haplotype frequencies were inferred separately for each
population by means of an expectation-maximization algorithm [42].
Association analyses were conducted using the statistical packages
SAS (version 9.0, SAS Institute, http://www.sas.com). EA and AA
groups were analyzed separately because allele and haplotype
frequencies were quite different between the two groups. Conformity
to the genotype frequencies expected under Hardy-Weinberg
equilibrium was examined for each SNP. The genetic effects of SNPs
on HIV-1 infection susceptibility were assessed by comparing allelic
and genotypic frequencies between HIV-1 HREU and HIV-1 SC
participants using the chi square or Fisher’s exact test. Regardless of
the exposure route, persons in the HREU or SN groups were at risk to
HIV-1 infection based on their inclusion in a HIV-1 risk group;
therefore, we combined participants across cohorts to achieve a
reasonable statistical power.
Kaplan-Meier survival statistics and the Cox proportional hazards
model (Cox model) were used to assess the effects of SNPs and
haplotypes on the rate of progression to AIDS. Two separate
endpoints reﬂecting advancing AIDS pathogenesis were considered
for SCs: (1) HIV-1 infection plus a decline of CD4þ T-cell counts
,200 cells/mm3 (CD4 ,200); (2) the 1987 Center for Disease Control
deﬁnition of AIDS (AIDS-87): HIV-1 infection plus AIDS-deﬁning
illness [43]. The signiﬁcance of genotypic associations and RH was
determined by unadjusted and adjusted Cox model regression
analyses. For each SNP, we compared the minor allele genotypes to
the most common genotype as a reference group. All p-values were
two-tailed. Genetic factors previously shown to affect progression to
AIDS were pre-determined to be included as confounding covariates
in the Cox model analysis: CCR5 D32, CCR2-64I, CCR5-P1, HLA-B*27,
HLA-B*57, HLA-B*35Px group (including HLA-B*3502, B*3503,
B*3504, and B*5301), and HLA Class I homozygosity for EA (reviewed
in [26,27]); HLA-B*57 and HLA Class I homozygosity for AA. CCR264I, HLA-B*27, and HLA-B*35Px were not considered as covariates
in AA due to no or weak effects in the AA participants, and CCR5
D32 was not considered due to its rarity in AA. Analyses were
stratiﬁed by sex and by age at seroconversion: 0–20, .20–40, and
.40 y [27]. Further stratiﬁcation by cohort was also performed for
the exploratory analyses. In the stratiﬁed Cox regression model, the
overall log-likelihood of hazards obtained is the sum over strata of
the stratum-speciﬁc hazards, as estimated by the method of partial
likelihood. As the same criteria for determining startpoints (seroconversion date) and endpoints and the similar sampling strategy
and follow-up settings were used across cohorts, we combined SCs
PLoS Pathogens | www.plospathogens.org

from all cohorts for the survival analysis to increase the power.
Although these cohorts differ in routes of HIV-1 transmission, no
appreciable effect of mode of infection on AIDS progression has
been found through re-analysis of more than ten thousands of SCs
from 38 studies around the world (including three used in this study)
[44].
To test the association of PPIA haplotypes and HIV-1 disease
progression, we ﬁrst performed a global test in the Cox regression
model for each of two disease outcomes separately for AA and EA.
The global null hypothesis is that the odds ratios of all haplotypes are
equal between cases and controls. Likelihood ratio tests were used to
compare a full model with all haplotypes and a base model with only
covariates. When the signiﬁcance of the global test exceeded a
relaxed nominal level, p , 0.10, the associations of individual
haplotypes were further tested.
To assess the level of correction factor for the number of SNPs,
assuming this was a discovery study, we applied spectral decomposition analysis [45]. This multiple testing correction method
assesses the equivalent level of independent SNPs taking account of
the extensive LD across PPIA. Based on spectral decomposition
analysis of SNPs in this study, a corrected p-value of 0.01 would be
equivalent to p ¼ 0.05. As this study was a conﬁrmation and extension
study of markers with previous positive association, uncorrected pvalues were reported.
Electrophoretic mobility-shift assay. Cell culture and an electrophoretic mobility-shift assay were performed as described [46].
Freshly explanted human T lymphocytes were obtained from normal
donors, puriﬁed by isocentrifugation, and activated for 72 h with 1
mg/ml PHA in RPMI 1640 medium containing 10% FCS (Sigma,
http://www.sigmaaldrich.com), 2 mM L-glutamine, and penicillinstreptomycin (50 IU/ml and 50 mg/ml, respectively). T lymphocytes
were made quiescent by washing and incubating for 24 h in RPMI
1640 medium containing 1% FCS before exposure to cytokines. Cells
were then stimulated with 100 nmol/L IL-4 (PeproTech, http://www.
peprotechec.com) or 100 nmol/L human rIL-2 (Hoffmann-La Roche,
http://www.roche.com) at 37 8C for 10 min. Cell pellets were frozen at
70 8C. The probe sequences were 59-ttgcgggcggggCcgaacgtggtat-39
for SNP3C and ttgcgggcggggGcgaacgtggtat-39 for SNP3G; 59ggcgggaggcCaggctcgtgccgtt for SNP4C, and 59- ggcgggaggcGaggctcgtgccgtt-39 for SNP4G allele; 59-aggaaaaccgtgtActattagccatggt-39 for SNP5A and 59-aggaaaaccgtgtGctattagccatggt-39 for
SNP5G (SNP site is capped). In cold oligonucleotide competition
assay, 100-fold excess of cold unlabeled probe was added as a
competitor. The band density was measured by using the software
ImageJ (http://rsb.info.nih.gov/ij/index.html). The sequence in and
around the SNP sites in the promoter region were searched for the
presence of transcription factor binding sites using the program
TESS: Transcription Element Search System (http://www.cbil.upenn.
edu/tess). Sequence alignment was performed using program ClustalW (http://www.ebi.ac.uk/clustalw).

Supporting Information
Table S1. Primers Used in the Resequencing of the PPIA Gene
Found at doi:10.1371/journal.ppat.0030088.st001 (17 KB XLS)
Table S2. Genotyping Methods for PPIA SNPs
!Found at doi:10.1371/journal.ppat.0030088.st002 (18 KB XLS)
Accession Numbers
The Entrez Gene databank (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼gene) accession numbers for the genes mentioned in this
paper are PPIA (5478) and TRIM5 (85363). The GenBank (http://www.
ncbi.nlm.nih.gov) accession numbers for the human and chimpanzee
PPIA genomic sequence are X52851 and NW_001237949, respectively. The Transfac binding site (http://www.cbil.upenn.edu/cgi-bin/
tess/tess) accession number is R04195 and R03868 for the SP1 factor.
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